Compare DOLE & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOLE | ARDX |
|---|---|---|
| Founded | 1851 | 2007 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2021 | 2014 |
| Metric | DOLE | ARDX |
|---|---|---|
| Price | $15.68 | $6.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $15.00 | ★ $15.14 |
| AVG Volume (30 Days) | 586.8K | ★ 3.0M |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.18% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $9,172,907,000.00 | $2,607,000.00 |
| Revenue This Year | $4.54 | $37.75 |
| Revenue Next Year | $1.83 | $34.24 |
| P/E Ratio | $29.34 | ★ N/A |
| Revenue Growth | ★ 8.23 | N/A |
| 52 Week Low | $12.52 | $3.50 |
| 52 Week High | $16.51 | $8.40 |
| Indicator | DOLE | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 65.90 | 56.13 |
| Support Level | $15.60 | $5.49 |
| Resistance Level | $15.73 | $6.23 |
| Average True Range (ATR) | 0.36 | 0.24 |
| MACD | 0.18 | 0.10 |
| Stochastic Oscillator | 96.81 | 94.53 |
Dole PLC operates in the North American and European markets for fresh fruits and vegetables. The company's segment includes Fresh Fruit; Diversified Fresh Produce - EMEA; Diversified Fresh Produce - Americas and ROW. It generates maximum revenue from the Diversified Fresh Produce - EMEA segment. Diversified Fresh Produce - EMEA segment includes Dole's Irish, Dutch, Spanish, Portuguese, French, Italian, U.K., Swedish, Danish, South African, Eastern European, and Brazilian businesses, the majority of which sell a variety of imported and local fresh fruits and vegetables through retail, wholesale and, in some instances, food service channels across the European marketplace. Geographically, the company operates in United States, Ireland, U.K. Spain, Sweden, and Others.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.